Eli Lilly & Co. (LLY) option IV near lower end of range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Deutsche Bank on Eli Lilly (LLY): 'CB-1 Appetite Suppression Looks Underwhelming'
September 20, 2024 11:37 AM EDTDeutsche Bank analyst James Shin reiterated a Buy rating and $1,025.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Ph2a results from NVO's monlunabant (CB-1) look underwhelming and in our view, removes the threat of a large well-capitalized, small-molecule competitor to LLY's orforglipron. Ph2a results for CB-1 in obese patients demonstrate a ~5.8% placebo-adjusted weight loss at 16 weeks for the 10mg dose.... More
